[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Xi L, Coello MC, Litle VR, Raja S, Gooding WE, Yousem SA, El-Hefnawy T, Landreneau RJ, Luketich JD, Godfrey TE: A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res; 2006 Apr 15;12(8):2484-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients.
  • Occult lymph node metastasis (micrometastasis) is a good prognostic indicator in non-small cell lung cancer (NSCLC) and could be used to direct adjuvant chemotherapy in stage I patients.
  • This study was designed to evaluate molecular markers for detection of occult lymph node metastasis in NSCLC, define the best marker or marker combination to distinguish positive from benign lymph nodes, and evaluate these markers in lymph nodes from pathologically node-negative (pN(0)) NSCLC patients.
  • A combination of three markers was further validated on an independent set of 32 benign lymph nodes, 38 histologically positive lymph nodes, and 462 lymph nodes from 68 pN(0) NSCLC patients.
  • The combination of these genes identified 32 of 462 (7%) lymph nodes from 20 of 68 (29%) patients as potentially positive for occult metastasis.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):389-98 [16495705.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):39-46 [11249047.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Pathol. 2001 Jul;194(3):298-302 [11439361.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491 [11882819.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Clin Chem. 2003 Feb;49(2):312-5 [12560358.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):611-8 [12845661.001]
  • [Cites] Am J Surg. 2003 Oct;186(4):324-9 [14553843.001]
  • [Cites] Clin Lung Cancer. 2004 Jan;5(4):214-25 [14967073.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2671-80 [15226334.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3417-20 [7542169.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4283-6 [7671236.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Oct;114(4):535-43 [9338638.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1410-5 [9801000.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):19-24 [10458213.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):896-900 [10489948.001]
  • [Cites] Chest. 2005 Feb;127(2):430-7 [15705978.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1099-109 [15709177.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2147-56 [15781625.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s [16000606.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s [16000607.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):429-35 [10646900.001]
  • (PMID = 16638856.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094059-04; United States / NCI NIH HHS / CA / R01 CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059; United States / NCI NIH HHS / CA / CA094059-03; United States / NCI NIH HHS / CA / R01 CA094059-01; United States / NCI NIH HHS / CA / R01 CA090665; United States / NCI NIH HHS / CA / R01 CA094059-03; United States / NCI NIH HHS / CA / R01CA90665; United States / NCI NIH HHS / CA / CA094059-02; United States / NCI NIH HHS / CA / CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059-02; United States / NCI NIH HHS / CA / R01 CA094059-04; United States / NCI NIH HHS / CA / CA094059-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DSG3 protein, human; 0 / Desmoglein 3; 0 / EPCAM protein, human; 0 / Pulmonary Surfactant-Associated Protein B
  • [Other-IDs] NLM/ NIHMS24707; NLM/ PMC1933488
  •  go-up   go-down


2. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • The most effective treatment of bronchial carcinoids and large cell neuroendocrine carcinoma in an early stage is complete surgical resection, whereas chemotherapy remains the primary treatment for small cell carcinoma.
  • The majority of patients with pulmonary carcinoid have an excellent survival, even if they present with lymph node metastases.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


3. Nakamachi H, Suzuki H, Akakura K, Imamoto T, Ueda T, Ishihara M, Furuya Y, Ichikawa T, Igarashi T, Ito H: Clinical significance of pulmonary metastases in stage D2 prostate cancer patients. Prostate Cancer Prostatic Dis; 2002;5(2):159-63
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of pulmonary metastases in stage D2 prostate cancer patients.
  • We retrospectively reviewed the PCa database to identify patients with pulmonary metastases at initial diagnosis.
  • The medical records of the patients were examined with respect to age, histologic grade, EOD score, marker response to endocrine therapy and clinical outcome.
  • We then compared several potential clinical factors between patients with and without pulmonary metastases.
  • A comparative study of stage D(2) patients with (n=20) and without (n=77) pulmonary metastases found no significant differences in EOD score, performance status, marker response and survival.
  • Only tumor grade was better in the group with, than without pulmonary metastases (P=0.0120, chi-square analysis).
  • In the series of autopsies, we found pulmonary metastases in 38 cases (63%), following metastases of the bone (57 cases, 95%) and lymph nodes (52 cases, 87%).
  • A retrospective analysis of survival showed that patients with bone or lymph node metastases had a positive relative risk.
  • These data suggest that the presence of pulmonary metastasis has no ominous impact on clinical course and disease outcome even in patients with disseminated prostate cancer.
  • [MeSH-major] Lung Neoplasms / secondary. Neoplasm Staging. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / pharmacology. Antineoplastic Agents, Hormonal / therapeutic use. Autopsy. Bone Marrow Neoplasms / secondary. Databases, Factual. Drug Resistance, Neoplasm. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Survival

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12497007.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


Advertisement
4. Umezu H, Chida M, Inoue T, Araki O, Tamura M, Tatewaki M, Fukushima Y, Honma K: Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease. Gen Thorac Cardiovasc Surg; 2010 Aug;58(8):434-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease.
  • We report a rare case of sarcoidosis that developed during induction chemotherapy for primary lung cancer, mimicking progressive disease.
  • Swelling of a pretracheal lymph node was also noted.
  • Thus, we gave induction chemotherapy consisting of paclitaxel (days 1, 8) + carboplatin (days 1, 8) for two cycles under clinical staging of T2N2M0.
  • After induction chemotherapy, (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) showed positive accumulation of FDG in mediastinal and bilateral hilar lymph nodes that had been negative in a previous FDG-PET examination, which led us to suspect disease progression.
  • Transbronchial lymph node biopsy results showed sarcoid granulomas in the specimens.
  • Following complete resection of the lung cancer, sarcoid granulomas were revealed in both nonneoplastic lung tissue and lymph nodes, which resulted in a diagnosis of lung cancer accompanied with sarcoidosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Sarcoidosis, Pulmonary / chemically induced
  • [MeSH-minor] Biopsy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Disease Progression. Fluorodeoxyglucose F18. Humans. Lymph Node Excision. Lymph Nodes / diagnostic imaging. Lymph Nodes / surgery. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Pneumonectomy. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):177-80 [9458317.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):90-5 [17272320.001]
  • [Cites] Scand J Respir Dis. 1975 May;56(1):20-7 [1145149.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Apr;53(4):196-8 [15875553.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Dec;128(6):892-9 [15573074.001]
  • [Cites] Jpn J Clin Oncol. 1996 Feb;26(1):18-23 [8551662.001]
  • [Cites] Respiration. 1993;60(2):133-6 [8341856.001]
  • [Cites] Intern Med. 2008;47(11):1021-5 [18520114.001]
  • [Cites] Chest. 2007 Apr;131(4):1019-27 [17426205.001]
  • (PMID = 20703868.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Rohde D, Schmidberger H, Uder M, Zeeb H, Association of Urologic Oncology of the German Cancer Society: Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int; 2010;85(1):1-10
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society.
  • The currently available guidelines on diagnosis and treatment of urogenital cancer do not provide the clinician with evidence-based recommendations for daily practice.
  • OBJECTIVES: To develop scientifically valid recommendations with regard to the most appropriate imaging technique and the most useful time interval in metastatic urogenital cancer patients undergoing systemic therapy.
  • METHODS: A systematic literature review was performed searching MedLine, Embase and Web of Science databases using the terms prostate, renal cell, bladder and testis cancer in combination with the variables lymph node, lung, liver, bone metastases, chemotherapy and molecular therapy, and the search terms computed tomography, magnetic resonance imaging and positron emission tomography were applied.
  • CONCLUSIONS: Contrast-enhanced computed tomography remains the standard imaging technique for monitoring of pulmonary, hepatic and lymph node metastases.
  • Bone scintigraphy is still the most widely used imaging technique for the detection and follow-up of osseous lesions.
  • Response assessment for patients treated with cytotoxic regime is best performed by the RECIST/WHO criteria; treatment response to molecular triggered therapy is best assessed by CT evaluating decrease in tumor size and density.
  • Cross-sectional imaging studies for response assessment might be obtained after each 2 cycles of systemic therapy to early stratify responders from non-responders.
  • [MeSH-major] Diagnostic Imaging. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Evidence-Based Medicine. Female. Humans. Male. Neoplasm Staging. Predictive Value of Tests. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20693823.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Ondrus D, Hornák M, Breza J, Mat'oska J, Schnorrer M, Belan V, Kausitz J: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol; 2001;32(4):665-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
  • INTRODUCTION: The therapeutic procedures in the management of testicular cancer are determined by histological findings in the removed testis and by the extent of the disease at the time of diagnosis.
  • However, all advanced tumors could be treated by primary chemotherapy regardless of the histological findings.
  • When the diagnosis of advanced tumor is evident, it is possible to start the treatment without orchiectomy.
  • The aim of this study was to evaluate the advantages of neo-adjuvant chemotherapy with delayed orchiectomy in the management of advanced testicular cancer.
  • MATERIAL AND METHODS: A total of 36 patients with advanced germ cell testicular cancer underwent primary PVB or BEP chemotherapy without previous orchiectomy.
  • Detailed medical, surgical and urological examination showed pulmonary metastases and/or extensive abdominal tumorous masses imitating acute abdominal crisis and impaired drainage of the kidney due to ureteral obstruction.
  • Eleven patients had a bulky disease in the retroperitoneum (Stage IIC), two had enlarged retroperitoneal lymph nodes (Stage IIB), two had enlarged mediastinal lymph nodes (Stage III) and other 16 patients had also pulmonary metastases, and 5 pts had pulmonary metastases only.
  • The patients were treated with cisplatin-containing combination chemotherapy.
  • Following completion of chemotherapy, orchiectomy was performed alone or simultaneously with retroperitoneal lymph node dissection (RPLND) and/or lung metastasectomy in cases with persistent residual mass.
  • Following orchiectomy the patients were regularly checked and in cases with viable malignant tumor found in the testis sequential chemotherapy was administered.
  • Similarly when the relapse of the disease was detected, the patients were treated with sequential chemotherapy.
  • RESULTS: Complete disappearance of metastases was observed in 12 patients following chemotherapy alone.
  • The viable tumor in the removed tissue was found in one patient.
  • Delayed orchiectomy was performed simultaneously with surgical removal of residual mass in the retroperitoneum in 24 patients and as a separate procedure in 12 patients who have been considered to be complete responders following chemotherapy alone.
  • Residual viable tumor in testicular specimen was found in three patients, necrotic or fibrotic tissue in 18, and mature teratoma in 15 patients.
  • Overall survival of the patients was 26/36 (72.7%) at mean of 56.9 months (range 7-145 months, median 50 months) since the start of the treatment.
  • CONCLUSIONS: In patients with advanced germ cell testicular cancer preference must be given to the early beginning of intensive chemotherapy without the need of tissue diagnosis of primary tumor that should be obtained by orchiectomy.
  • Benefit of this therapeutic approach is the timely management of acute abdominal and/or pulmonary symptoms of life-threatening distant metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Germinoma / drug therapy. Orchiectomy. Testicular Neoplasms / drug therapy. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm, Residual. Survival Rate. Teratoma / secondary. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1984 Sep;2(9):1025-7 [6088708.001]
  • [Cites] J Urol. 1983 Mar;129(3):522-3 [6834536.001]
  • [Cites] J Urol. 1996 Mar;155(3):952-4 [8583615.001]
  • [Cites] Br J Cancer. 1983 May;47(5):613-9 [6189504.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1018-24 [7842403.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] J Urol. 1986 Dec;136(6):1221-3 [3022018.001]
  • (PMID = 11989561.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; PVB protocol
  •  go-up   go-down


7. Kijima Y, Umekita Y, Yoshinaka H, Owaki T, Sakamoto A, Yoshida H, Aikou T: A case of breast carcinoma with cartilaginous and osseous metaplasia. Breast Cancer; 2006;13(2):214-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neither axillary lymph node metastases nor vessel invasion were observed.
  • Five months after the operation, she developed lung metastases.
  • Although she received systemic chemotherapy, the lesions increased in number and grew rapidly.
  • She died of pulmonary distress 5 months after relapse.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinosarcoma / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy, Needle. Diagnosis, Differential. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Mammography. Mastectomy, Segmental. Metaplasia. Middle Aged. Risk Assessment


8. Sonobe M, Bando T, Date H: Peripheral primitive neuroectodermal tumour of the chest wall invading lung with regional lymph node metastasis. Eur J Cardiothorac Surg; 2009 Jan;35(1):185-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumour of the chest wall invading lung with regional lymph node metastasis.
  • Here we present the case of a 26-year-old man in whom peripheral primitive neuroectodermal tumour of chest wall origin invaded the left lung with regional lymph node metastasis.
  • He underwent initial resection of the left chest wall tumour with combined left lower lobectomy, left S5 segmentectomy, and lymph node dissection in order to facilitate a definitive diagnosis and also to obviate the risk of fatal bleeding due to tumour invasion of the pulmonary artery.
  • Histological examination of the resected sample revealed small round cell proliferation with neural differentiation, and confirmed lymph node involvement within the left lower lobe.
  • Diagnosis of peripheral primitive neuroectodermal tumour was confirmed.
  • After surgery, combination chemotherapy with cyclophosphamide, vincristine, doxorubicin, ifosphamide, and etoposide was given.
  • [MeSH-minor] Adult. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036597.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Zhang LB, Sun YE, Yu CH, Liu Y: [Clinical diagnosis and surgical treatment of primary pulmonary lymphoma]. Zhonghua Wai Ke Za Zhi; 2006 Jan 15;44(2):97-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis and surgical treatment of primary pulmonary lymphoma].
  • OBJECTIVE: To study the clinical characteristics, the principles of diagnosis and surgical treatment for primary pulmonary lymphoma.
  • METHOD: Ten patients with primary pulmonary lymphoma were treated surgically and their clinical characteristics, the experiences of clinical diagnosis and surgical treatment were analyzed.
  • Imageological representations (X-ray and CT scanning of thorax) were similar to primary pulmonary carcinoma.
  • Eight cases were mistakenly diagnosed as primary pulmonary carcinoma by imageological representations.
  • Only 2 cases were diagnosed as primary pulmonary lymphoma by percutaneous needle biopsy and pathologic examination.
  • All cases with non-Hodgkin's lymphoma received regular chemotherapy (MOPP and ABVD scheme for 1 case with Hodgkin's disease respectively, CHOP for 8 cases with non-Hodgkin's lymphoma), and 3 cases received radiotherapy postoperatively.
  • RESULTS: Eight cases were non-Hodgkin's lymphoma (B-type) and 2 cases were Hodgkin's disease (mixed type) confirmed by pathological examination.
  • Two cases with non-Hodgkin's lymphoma (stage II 2E, B-cell, low-grade) and 2 cases with Hodgkin's disease (stage IE and II 2E, mixed type) died in 24, 32, 8 and 17 months postoperatively respectively.
  • CONCLUSIONS: Primary pulmonary lymphoma is a rare type of malignant lung neoplasm without special clinical features.
  • The preoperative diagnosis is difficult.
  • Treatment modalities include surgical treatment, radiotherapy and regular chemotherapy postoperatively.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Lymphoma / diagnosis. Lymphoma / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Pneumonectomy / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620666.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Massone PP, Lequaglie C, Macnani B, Conti B, Cataldo I: [Significance of video-assisted thoracoscopic surgery in the diagnosis and staging of primary pulmonary neoplasms]. Chir Ital; 2001 May-Jun;53(3):291-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of video-assisted thoracoscopic surgery in the diagnosis and staging of primary pulmonary neoplasms].
  • The authors describe the usefulness of video-assisted thoracoscopic surgery (VATS) in the staging and diagnosis of primary lung cancer.
  • Forty-four patients underwent a thoracoscopic lymph node biopsy (95%), while in 2 subjects, in whom pleural metastases were found, the histological diagnosis was established by pleural metastatic nodule thoracoscopic biopsy (5%).
  • A VATS lymph node biopsy was performed in 16 cases at level 5 (35%), in 13 at level 6 (28%), in 9 at level 7 (19%) and in 6 at level 8 (13%).
  • Lymph node biopsies were ipsilateral in 37 patients (80%) and contralateral in 7 (15%).
  • The subsequent treatment was neoadjuvant chemotherapy for stage III A patients and chemotherapy in association with radiotherapy for stage III B subjects.
  • The patients with microcytoma underwent integrated radiotherapy and chemotherapy and pan-encephalic radiotherapy.
  • Sixteen patients, with negative frozen-section histological findings for mediastinal lymph node neoplastic disease, underwent pulmonary resection after thoracotomy in the same operating session (35%) and were subsequently classified as stages I and II.
  • In conclusion, VATS proved extremely useful in the diagnosis and staging of patients affected by lung cancer with synchronous lymph node enlargement.
  • This procedure allowed the diagnosis of suspect involved mediastinal lymph nodes in all cases thus affected and the exclusion of lymph node disease in patients subsequently treated by lung resection in a single session.
  • The precise staging obtained then made it possible to direct the patients towards the most appropriate form of treatment.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11452813.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Okubo K, Kobayashi M, Morikawa H, Hayatsu E: Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy. Jpn J Thorac Cardiovasc Surg; 2006 Jul;54(7):268-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy.
  • OBJECTIVE: Induction chemoradiotherapy followed by anatomical resection is a current therapeutic strategy for non-small-cell lung cancer with mediastinal node involvement.
  • Dense peritracheal fibrosis and sclerosis after chemoradiotherapy cause difficult mediastinal node dissection.
  • We evaluated a novel technique to make the mediastinal node dissection easier after induction therapy.
  • METHODS: At the end of mediastinoscopic node biopsy for staging of lung cancer, cotton-type collagen was inserted anterior and lateral to the trachea in patients with pathologically confirmed mediastinal node involvement (n=45).
  • The induction therapy consisted of concurrent use of platinum-based chemotherapy and hyperfractionated radiotherapy.
  • After the chemoradiotherapy all patients underwent a pulmonary resection with complete mediastinal node dissection 7-12 weeks after the collagen insertion.
  • Surgical findings of the mediastinum and the time for node dissection were compared with those without collagen insertion at mediastinoscopy after chemoradiotherapy (n=5).
  • Mediastinal node dissection was easily accomplished by removing mediastinal tissues lateral and anterior to the collagen.
  • The rate of mediastinal node separation was significantly higher with collagen insertion than without (p<0.0001).
  • The times for node dissection in patients with and without collagen insertion showed no significant difference.
  • CONCLUSION: Cotton-type collagen insertion at staging mediastinoscopy for lung cancer separates the mediastinal nodes from the trachea and makes the node dissection easier after induction chemoradiotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / therapy. Collagen / therapeutic use. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Lymph Node Excision. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / surgery. Mediastinoscopy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Japan. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Sentinel Lymph Node Biopsy. Trachea / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898638.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


12. Aketa A, Yamada G, Aketa K, Ohnishi T, Takahashi Y, Kudoh K, Tanaka S, Shiratori M, Takahashi H, Watanabe A, Satoh M, Abe S: [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma]. Nihon Kokyuki Gakkai Zasshi; 2004 Feb;42(2):164-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma].
  • We report 2 cases of pulmonary pleomorphic carcinoma.
  • However, we performed partial resection of the tumor because it had invaded the aorta, pulmonary artery, pericardium and pleura.
  • The pathological diagnosis was pleomorphic carcinoma, p-T4 N2 M0.
  • After the operation, we performed systemic chemotherapy, including cisplatin and irinotecanm with little effect (PD).
  • However, we performed left upper segmentectomy and lymph node dissection because of invasion of the aorta and the chest wall, and because of hypersegmentation of the left upper lobe.
  • Pathological diagnosis was pleomorphic carcinoma, p-T4 N0 M0.
  • After the operation, the mediastinum was subjected to radiation therapy.
  • We performed systemic chemotherapy with substances including cisplatin, gemcitabine and vinorelbine, but with little effect (PD).
  • Both cases had rapidly growing neoplasms showing little sensitivity to chemotherapy or radiotherapy.
  • Pulmonary pleomorphic carcinoma is suggested to be type of lung cancer with a poor prognosis when the tumor is not resected in the early stages.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neoplasms, Multiple Primary
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Age Factors. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15007917.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Warwick R, Page R: Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol; 2007 Dec;33 Suppl 2:S59-63
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of pulmonary metastases from colorectal carcinoma.
  • Although pulmonary metastases from colorectal carcinoma (CRC) often represent systemic and uncontrolled tumour growth, in a number of patients lung disease is limited and the patient remains well.
  • Chemotherapy, the only alternative treatment only very rarely leads to survival beyond 24 months.
  • Pulmonary metastases which are suitable for resection are usually detected on chest radiography, especially when carried out during monitoring of patients.
  • CT scans supplemented by PET scans usually confirm the diagnosis, but percutaneous biopsy is sometimes necessary to exclude a primary lung cancer.
  • The criteria for resecting CRC pulmonary metastases are (1) the primary tumour is controlled or is controllable;.
  • (2) complete resection is possible; and (3) the patient has adequate pulmonary reserve to tolerate the planned resection.
  • The majority of patients having resection of pulmonary metastases from CRC recover well with very few post-operative complications.
  • Following resection favourable prognostic factors include a long disease-free interval, small number and small size of metastases, a normal carcinoembryonic antigen level, and an absence of concomitant liver metastases and mediastinal lymph node spread.
  • Surgery for pulmonary metastases of CRC remains the best means of local control and the best way to render the patient disease-free.
  • Patients with complete resection of pulmonary metastases have an improved long-term survival when compared to patients with unresected metastases.
  • [MeSH-major] Colorectal Neoplasms / therapy. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neoplasm Recurrence, Local / surgery. Patient Selection. Survival Analysis. Thoracic Surgery, Video-Assisted. Thoracotomy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023132.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 37
  •  go-up   go-down


14. Iwata T, Nishiyama N, Inoue K, Kawata Y, Izumi N, Tsukioka T, Shinkawa K, Suehiro S: Biphasic pulmonary blastoma: report of a case. Ann Thorac Cardiovasc Surg; 2007 Feb;13(1):40-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic pulmonary blastoma: report of a case.
  • Chest computed tomography (CT) showed a large mass about 7 cm in diameter in the right lower lobe.
  • A biphasic pulmonary blastoma was histologically diagnosed by a characteristic finding that it was mainly constituted of immature tumor tissue that had both epithelial and mesenchymal components.
  • No mediastinal lymph node metastasis was proven.
  • Stage T2N0M0 disease was diagnosed, and the patient chose not to undergo postoperative adjuvant chemotherapy; he remains well without recurrence 36 months after the operation.
  • [MeSH-major] Lung Neoplasms / diagnosis. Pulmonary Blastoma / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Humans. Male. Neoplasm Staging. Pneumonectomy

  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392670.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Sherer DM, Stimphil RG, Santoso P, Demetus S, Abulafia O: Stage IV large B cell lymphoma presenting as gigantomastia and pulmonary hypertension. Obstet Gynecol; 2004 May;103(5 Pt 2):1061-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV large B cell lymphoma presenting as gigantomastia and pulmonary hypertension.
  • BACKGROUND: Gigantomastia is a rare complication of pregnancy usually associated with benign conditions, including end-organ hypersensitivity to normal hormone levels, penicillamine therapy, mirror syndrome, and benign or glandular fibroadenomas.
  • Echocardiography performed because of the patient's tachypnea and tachycardia disclosed pulmonary hypertension.
  • After spontaneous delivery, core needle breast and axillary lymph node biopsies and computerized tomography imaging were performed, and stage IV diffuse large B cell lymphoma with infiltration of the breasts was confirmed.
  • The patient responded to systemic chemotherapy with resolution of the gigantomastia and pulmonary artery hypertension.
  • CONCLUSION: This case demonstrates that systemic malignancies such as diffuse large B cell lymphoma should be considered in the differential diagnosis of gigantomastia during pregnancy.
  • In addition, malignancy-related pulmonary hypertension during pregnancy may be reversible after chemotherapy, as reported in nonpregnant patients.
  • [MeSH-major] Breast Diseases / etiology. Hypertension, Pulmonary / etiology. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Axilla. Biopsy, Needle. Breast / pathology. Female. Humans. Lymph Nodes / pathology. Neoplasm Staging. Pregnancy


16. Yung RC: Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy. Respir Care Clin N Am; 2003 Mar;9(1):51-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy.
  • In pursuing a tissue diagnosis of a suspected lung cancer, there is a range of procedures to choose from.
  • The principal goals are ideally to diagnose and pathologically stage the patient's lung cancer at the same time, preferably by using the safest, least invasive, and least costly tests.
  • If there is clinical or radiographic evidence of extrapulmonary spread of disease, including supraclavicular N3 nodal involvement or a malignant pleural effusion, then radiology-guided or open biopsy will confirm tumor cell type and stage the patient as unresectable.
  • Bronchoscopy with direct examination of the visible airways is most often the preferred invasive diagnostic procedure.
  • Although the procedure should be geared toward sampling the highest staged lesion to provide an accurate tissue staging at the time of diagnosis, additional procedures can be performed in sequence to sample different nodal stations, is well as the primary lung mass.
  • The incidental finding of an unexpected central airways lesions or a synchronous second endobronchial lung primary will also affect plans for treatment.
  • For visible endobronchial lesions, given the similar yield of EBBX and EBNA, EBNA may provide an immediate diagnosis, thus obviating additional, possibly morbid, procedures such as BB or EBBX.
  • Under all circumstances, immediate cytology feedback with ROSE will confirm the adequacy of the retrieved specimen for a definitive tissue diagnosis, thus avoiding the need for extra biopsies, or worse yet, the need for a second invasive procedure because of insufficient diagnostic material.
  • ROSE is educational to the clinician and fellow-in-training in getting immediate feedback on the procedural techniques and in learning pulmonary pathology, as well.
  • The diagnostic sensitivity of TTNA is high, especially for the larger peripheral-based lung lesion, and TTNA is a relatively rapid procedure.
  • Furthermore, TTNA usually does not provide information about nodal staging, unless the TTNA is initially directed toward central lymph nodes.
  • TTNA may then provide the tissue diagnosis to permit initiation of cytotoxic chemotherapy and radiotherapy.
  • TTNA may also be helpful in cases where the likelihood of cancer is only intermediate, such that a specific benign diagnosis or an adequate sample without cancer will greatly reduce the likelihood ratio of missing a cancer, and justify to the patient and physician an approach of careful observation.
  • To maximize the yield of these diagnostic procedures, there must be continued improvement in the hands-on teaching of clinical fellows and pulmonary practitioners in the use of the various techniques of TBNA and TBBX, as well as the applications of new endoscopic technology, such as EBUS.
  • Definitive curative surgery remains the goal for patients with lung cancer, with accurate pathological staging performed intraoperatively.
  • Therefore, for patients with sufficient cardiopulmonary reserve who can be clinically staged as IA or IB, either by good quality CT with contrast or increasingly with 18-FDG PET, the initial tissue diagnosis may be at the time of surgery, when a frozen section preceding a complete lobectomy with lymph node sampling will combine diagnosis and therapy.
  • [MeSH-major] Biopsy, Needle / methods. Bronchoscopy / methods. Cytodiagnosis. Lung Neoplasms / diagnosis. Mediastinal Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820712.001).
  • [ISSN] 1078-5337
  • [Journal-full-title] Respiratory care clinics of North America
  • [ISO-abbreviation] Respir Care Clin N Am
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58184
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 159
  •  go-up   go-down


17. Yonemori K, Kunitoh H, Sekine I: Small-cell lung cancer with lymphadenopathy in an 18-year-old female nonsmoker. Nat Clin Pract Oncol; 2006 Jul;3(7):399-403; quiz following 403
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An asymptomatic 18-year-old female presented in December 2002 with a left pulmonary mass, and an enlarged mediastinum and left hilum, detected on a routine chest X-ray.
  • Superficial lymph nodes were not palpable.
  • A CT scan of the chest disclosed a round tumor in the left lower lobe and marked enlargement of the ipsilateral hilar and mediastinal lymph nodes.
  • DIAGNOSIS: Limited-stage small-cell lung cancer (T1N2M0, clinical stage IIIA).
  • MANAGEMENT: Etoposide plus cisplatin chemotherapy with concurrent accelerated hyperfractionated thoracic radiotherapy, left pneumonectomy and lymph-node dissection.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Smoking


18. Miura H, Taira O, Hiraguri S, Maeda J, Kato H: Recurrent squamous cell carcinoma of the breast with undifferentiated features: report of a case. Surg Today; 2002;32(10):891-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinoma of the breast is a rare type of cancer, the origin of which is still uncertain.
  • Echography showed a 46 x 29 x 23-mm mass with cavity formation, and aspiration cytology confirmed a diagnosis of squamous cell carcinoma.
  • A modified radical mastectomy with level III lymph node dissection was performed.
  • Despite intensive therapy including chemotherapy (CEF: cyclophosphamide, epirubicin, 5-fluorouracil) and irradiation (50 Gy), the patient died from pulmonary and skin metastases 20 months after her initial operation.
  • Immunohistochemical findings indicated the possibility that the squamous cell carcinoma developed from noninvasive ductal carcinoma of the comedo type, and that the undifferentiated cells from the site of recurrence developed from dedifferentiation of the squamous cell carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymph Node Excision. Male. Mastectomy, Modified Radical. Middle Aged. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12376787.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Katsuta E, Ohkubo T, Someno Y, Saguchi M, Aoyagi H, Takahata T, Hasegawa K, Hamada S, Kaneko J, Maejima S: [A long-term survival case of local recurrence of breast cancer treated with combined modality therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2760-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
  • In 1997, the patient underwent pectoral muscle-preserving mastectomy and axillary/subclavicular lymph node dissection for the treatment of right breast cancer.
  • Histological diagnosis was invasive ductal carcinoma (T2, N2, M0, Stage IIIA).
  • She received a combination therapy with TAM and UFT for 5 years postoperatively.
  • Because tumor recurrence occurred in right axillary lymph nodes in the 9th postoperative year, the patient underwent resection of these lymph nodes followed by 6 cycles of AC-based chemotherapy.
  • Multiple lung metastases occurred in the 10th postoperative year, and then, the patient received 8 cycles of DOC-based chemotherapy.
  • In the 11th postoperative year, a mass appeared again in the right axilla, and 6 cycles of capecitabine-based chemotherapy was administered.
  • In the 12th postoperative year, pulmonary metastasis was in progression and an increased right axillary mass were noted.
  • Six cycles of combined trastuzumab+PTX therapy were administered.
  • The patient is scheduled to receive a postoperative radiotherapy, followed by resumption of chemotherapy.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Mastectomy. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Tamoxifen / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage. Trastuzumab. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224704.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 56HH86ZVCT / Uracil; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel; 1-UFT protocol
  •  go-up   go-down


20. Ruhland B, Dittmer C, Thill M, Diedrich K, Fischer D: Metastasized hemangiopericytoma of the breast: a rare case. Arch Gynecol Obstet; 2009 Sep;280(3):491-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma, leiomyosarcoma, rhabdomyosarcoma, as well as hemangiopericytoma, are part of the soft tissue sarcoma group.
  • We present the case of a woman, who received primary diagnosis of a malignant hemangiopericytoma of the left breast.
  • She underwent a mastectomy with an axillary lymph node sampling (stage pT3 pN0 cM0), as adjuvant therapy was not mandatory.
  • Eight months after diagnosis, the patient presented with lumbar back pain, gluteal pain and right accentuated adynamia in both legs because of a disseminated osseous metastasis.
  • Diagnostic investigation presented a cerebral, pulmonary, cutaneous, hepatic and pleural metastatic disease.
  • Two months after initiation of chemotherapy the patient died.
  • Diagnostic criteria and treatment principles in the metastatic situation are presented in addition to the literature to give a review about this rare malignancy.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy
  • [MeSH-minor] Aged. Axilla. Fatal Outcome. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169699.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Fernández Gómez JM, Escaf Barmadah S, Guate Ortiz JL, Martín Huescar A, Fresno Forcelledo F, García Rodríguez J, Rodríguez Faba O, Jalón Monzón A, Rodríguez Martínez JJ: [Urologic treatment of testicular germ cell cancer]. Arch Esp Urol; 2002 Oct;55(8):927-36
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urologic treatment of testicular germ cell cancer].
  • [Transliterated title] Tratamiento urológico del cáncer germinal de testículo.
  • OBJECTIVE: To review the treatment of testicular germ-cell cancer in our series.
  • METHODS: 73 cases with the diagnosis of germ-cell testicular tumours were reviewed.
  • We reviewed the treatment options employed in our series, analysing different currently recognised risk factors.
  • Inguinal orchiectomy was performed in all cases except 5 patients in whom tumours were incidentally diagnosed (atrophic testis orchiectomy, hydrocelectomy, trauma) and underwent ipsilateral scrotal excision in a second time.
  • 30 patients received chemotherapy after orchiectomy: 3 metastatic seminomas (stage II) (8.8% of seminomas treated with chemotherapy) and 27 non seminomatous tumours (69.2% of them).
  • Relapses appeared in the retroperitoneum in 11 cases (84.6%), 2 of them concurrent with pulmonary relapse; 1 patient had liver relapse, one lung and another in bone.
  • Median time to relapse was 4 months (2-102).
  • Orchiectomy is the primary treatment and allows determination of the dissemination risk.
  • Radiotherapy is very effective for localised seminomas with poor prognostic factors, and for non seminomas 2 cycles of chemotherapy seem to be an effective approach, as well as of little toxicity.
  • We must know and apply optimised programs for observation of these tumours (stage I), and also use follow-up protocols after chemotherapy or radiotherapy.
  • Some cases need complex surgery for residual masses resection or post chemotherapy salvage surgery in disseminated tumours (Stages II & III).
  • Sterility treatment protocols are applied to preserve fertility.
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / secondary. Seminoma / drug therapy. Seminoma / pathology. Seminoma / radiotherapy. Seminoma / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12455283.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


22. Amin RM, Kokubo T, Hiroshima K, Narita M, Itou K, Kuroki M, Tanizawa T, Nakatani Y: Metastatic germ cell tumor of the lung masquerading as primary rhabdomyosarcoma. Pathol Int; 2005 Oct;55(10):649-54
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two years after testicular resection was carried out in a 40-year-old man that revealed mixed germ cell tumor of more than one histological type (seminoma, embryonal cell carcinoma, and yolk sac tumor), he presented with an asymptomatic pulmonary nodule in his left lower lobe.
  • Video-assisted thoracoscopic partial resection of the tumor revealed a 24 x 20 mm teratoma with somatic-type malignancy in which pleomorphic rhabdomyosarcoma was a major element.
  • Throughout the course there was no abdominal lymph node swelling detected by computed tomography (CT) and tumor markers were normal.
  • Adjuvant chemotherapy was started after the tumor recurrence.
  • Currently, the patient is still undergoing chemotherapy 5 months after the tumor recurrence.
  • In conclusion, despite the fact that primary pulmonary rhabdromyosarcoma is a rare neoplasm, metastatic pulmonary germ cell tumor with somatic-type malignancy showing predominantly rhabdomyosarcomatous differentiation should be considered in the differential diagnosis of such lesions of the lung.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Rhabdomyosarcoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Male. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185296.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Yamasaki T, Shimazaki H, Aida S, Tamai S, Tamaki K, Hiraide H, Mochizuki H, Matsubara O: Primary small cell (oat cell) carcinoma of the breast: report of a case and review of the literature. Pathol Int; 2000 Nov;50(11):914-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was alive and well without disease 16 months after modified radical mastectomy and subsequent chemotherapy.
  • Review of nine previously reported cases and this case of primary small cell carcinoma of the breast has revealed that this type of tumor shows prominent vascular invasion, frequent lymph node metastasis, infrequent expression of estrogen receptor, and also very poor prognosis.
  • Immunohistochemical study for the c-kit proto-oncogene product, which has been reported to be a specific marker for pulmonary small cell carcinoma, demonstrated positive reactivity in approximately 80% of the tumor cells of this case, which is the first report according to our knowledge.
  • The expression of c-kit might be some aid to the diagnosis of primary small cell carcinoma of the breast.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. Cytoplasmic Granules / ultrastructure. Female. Humans. Immunohistochemistry. Mastectomy, Modified Radical. Neoplasm Proteins / analysis. Neurosecretory Systems / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11107070.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 21
  •  go-up   go-down


24. Takagi Y, Nakamura H, Miwa K, Adachi Y, Fujioka S, Haruki T, Taniguchi Y: A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy. Thorac Cardiovasc Surg; 2010 Aug;58(5):304-6
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy.
  • A 10-cm mass was found to be present in the right pulmonary apical region on chest X-ray examination.
  • The mass was diagnosed as a G-CSF-producing invasive apical cancer and the patient underwent chemoradiotherapy followed by right upper lobectomy with combined resection of the chest wall, and lymph node dissection.
  • A very small nodule was noted in the right frontal lobe on brain MRI before surgery, and the final diagnosis was pT3N0M1, stage IV lung adenocarcinoma.
  • For the brain metastasis, gamma knife treatment and chemotherapy were performed after surgery, and there was no recurrence during 16 months after surgery.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / blood. Lung Neoplasms / therapy. Lymph Node Excision. Pneumonectomy
  • [MeSH-minor] Biopsy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Neurosurgical Procedures. Positron-Emission Tomography. Radiotherapy, Adjuvant. Thoracic Wall / pathology. Thoracic Wall / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20680910.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


25. Huang GS, Juretzka M, Ciaravino G, Kohler S, Teng NN: Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. Gynecol Oncol; 2002 Dec;87(3):313-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma.
  • BACKGROUND: Primaryadenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established.
  • CASE: A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease.
  • Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection.
  • She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions.
  • Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life.
  • She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis.
  • CONCLUSIONS: We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Doxorubicin / therapeutic use. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Resistance, Neoplasm. Female. Humans. Neoplasm Metastasis. Paget Disease, Extramammary / complications

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468332.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


26. Zielinski M, Hauer J, Hauer L, Pankowski J, Nabialek T, Szlubowski A: Staging algorithm for diffuse malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg; 2010 Feb;10(2):185-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An algorithm of preoperative mediastinal nodal staging with endobronchial/endoesophageal ultrasonography (EBUS/EUS) and transcervical extended mediastinal lymphadenectomy (TEMLA) combined with laparoscopy/peritoneal lavage and cytology was analyzed to establish the realistic criteria for radical multimodality treatment of malignant pleural mesothelioma (MPM).
  • The algorithm included computed tomography (CT), thoracoscopy with multiple pleural biopsies and talc pleurodesis, EBUS/EUS and one-stage TEMLA and laparoscopy/peritoneal lavage and cytology of the fluid.
  • There were 16 women and 26 men in ages ranging from 43 to 77 years (mean 57.8); 31 epithelioid, 2 sarcomatoid and 9 biphasic type MPM.
  • 21/42 patients were considered possible candidates for multimodality treatment.
  • Three patients who received neoadjuvant chemotherapy were excluded from this study.
  • [MeSH-major] Algorithms. Mesothelioma / diagnosis. Neoplasm Staging / methods. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy. Chemotherapy, Adjuvant. Endosonography. Female. Humans. Laparoscopy. Lymph Node Excision. Lymphatic Metastasis. Male. Medical Futility. Middle Aged. Patient Selection. Peritoneal Lavage. Pleurodesis. Predictive Value of Tests. Radiotherapy, Adjuvant. Thoracoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843550.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Shimizu Y, Tsunezuka Y, Tanaka N: [A case of unresectable advanced thymic carcinoma in an elderly woman responding to S-1 with good QOL maintained]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1977-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After hospitalization, CT-guided biopsy was performed, but did not lead to diagnosis.
  • Therefore, surgical biopsy was performed and the diagnosis was advanced thymic carcinoma with metastasis to the mediastinal lymph node, pericardium invasion and left lung invasion.
  • In consideration of her advanced age and a low pulmonary function, it was thought that the radical operation was impossible.
  • Because the patient strongly hoped for oral chemotherapy on an outpatient basis, we started treatment with S-1 100 mg/day (3 weeks administration, 2 weeks withdrawal).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / therapeutic use. Quality of Life. Tegafur / therapeutic use. Thymoma / drug therapy. Thymoma / pathology
  • [MeSH-minor] Aged. Biopsy. Drug Combinations. Female. Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011356.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


28. Nagashima T, Mizutani Y, Kawahara H, Maguchi S, Terayama Y, Shinohara T, Orba Y, Chuma T, Mano Y, Itoh T, Sawa H, Sakai K, Motomura M, Nagashima K: Anti-Hu paraneoplastic syndrome presenting with brainstem-cerebellar symptoms and Lambert-Eaton myasthenic syndrome. Neuropathology; 2003 Sep;23(3):230-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary X-ray findings, class IIIb sputum cytology, and positive anti-Hu antibody established the diagnosis of PNS associated with small-cell lung cancer (SCLC).
  • Two cycles of combined chemotherapy resulted in shrinkage of the lung tumor together with complete recovery of neurological symptoms and disappearance of anti-Hu antibody.
  • Relapse of SCLC 4 months later with re-appearance of anti-Hu antibody required additional chemotherapy and irradiation.
  • Eight months later, when multiple liver metastasis of SCLC was noticed, muscular weakness with positive waxing phenomenon compatible with Lambert-Eaton myasthenic syndrome (LEMS) developed.
  • Postmortem examinations revealed residual SCLC in the primary lung, and massive liver metastasis with generalized lymph node involvement, but no tumors in the CNS.
  • [MeSH-major] Carcinoma, Small Cell / complications. Lambert-Eaton Myasthenic Syndrome / etiology. Lung Neoplasms / complications. Neoplasm Recurrence, Local / immunology. RNA-Binding Proteins / immunology

  • Genetic Alliance. consumer health - Lambert Eaton myasthenic syndrome.
  • Genetic Alliance. consumer health - Lambert syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14570293.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / ELAV Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


29. Krajewska J, Olczyk T, Roskosz J, Paliczk-Cieślik E, Smietana AK, Kaczmarek-Borowska B, Jarząb B: Treatment with sorafenib in advanced thyroid cancer - a case report. Endokrynol Pol; 2010 Sep-Oct;61(5):492-6
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with sorafenib in advanced thyroid cancer - a case report.
  • The treatment, including total thyroidectomy and complementary radioiodine (RAI) therapy, gives complete remission in 90% of patients.
  • In the group of patients with disease progression and no 131I uptake, searching for new therapeutic modalities before all tyrosine kinase inhibitors and other antiangiogenic agents is necessary.
  • Primary treatment by total thyroidectomy and 131I ablation led to complete remission.
  • In 2000 local as well as lymph node recurrence was diagnosed and successively treated by surgery.
  • Treatment with increasing doses of thalidomide (up to 800 mg/d) was administered for 3 months with a good tolerance; however, the therapy was withdrawn due to cancer progression.
  • Radiological examination performed after 16 weeks confirmed stable disease, whereas 2 months later, after sorafenib withdrawal due to lack of treatment possibility, further progression was observed.
  • Metronomic chemotherapy with Adriamycin was instituted which gave disease stabilization for 6 months.
  • The patient died with advanced disseminated disease due to pulmonary embolism.
  • We present this case to document no adverse effects of therapy with sorafenib in a patient with brain DTC metastases.
  • Sorafenib therapy was only short-term, but no progression occurred in this time.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Pyridines / administration & dosage
  • [MeSH-minor] Carcinoma. Doxorubicin / administration & dosage. Fatal Outcome. Humans. Hypoparathyroidism / complications. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Reoperation. Thalidomide / administration & dosage. Thyroid Neoplasms / complications. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary. Thyroid Neoplasms / surgery. Thyroidectomy. Ultrasonography

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049464.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 4Z8R6ORS6L / Thalidomide; 80168379AG / Doxorubicin; 9ZOQ3TZI87 / sorafenib; Thyroid cancer, papillary
  •  go-up   go-down


30. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y: Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. Int J Hematol; 2003 Nov;78(4):357-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.
  • Computed tomography scans showed extensive thickening of the gastric wall and bilateral massive PE without lymph node or pulmonary involvement.
  • The diagnosis was gastric mucosa-associated lymphoid tissue (MALT) lymphoma infiltrating to the PE, PB, and BM.
  • The patient had a good response to fludarabine treatment, which was followed with rituximab therapy.
  • [MeSH-minor] Aged. Antigens, Differentiation, B-Lymphocyte / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. B-Lymphocytes / pathology. Cell Adhesion Molecules / analysis. Cell Differentiation. Cell Division. Humans. Immunophenotyping. Male. Neoplasm, Residual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Blood. 2002 Jan 1;99(1):3-9 [11756145.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2019-27 [10595932.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):798-805 [11504840.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1183-8 [11193437.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):588-94 [11736940.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40 [11842387.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):683-90 [11710684.001]
  • [Cites] Gut. 2001 Oct;49(4):519-25 [11559649.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1583-93 [9137085.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Leuk Res. 1990;14(7):617-22 [2388473.001]
  • [Cites] Acta Otolaryngol Suppl. 1996;523:259-62 [9082801.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):113-7 [10704680.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • (PMID = 14686495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Cell Adhesion Molecules; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


31. Ou HY, Hung CJ, Hsu WH, Yu EH, Wu TJ: Variability of clinical presentations in three cases of parathyroid carcinoma. J Formos Med Assoc; 2003 Apr;102(4):266-9
Genetic Alliance. consumer health - Parathyroid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis depends largely on the extent of successful resection at the time of initial operation.
  • Therefore, early diagnosis before surgery is important.
  • The first patient, a 20-year-old uremic female, had refractory hypercalcemia after 5 years of hemodialysis treatment.
  • Multiple pulmonary metastases were found later.
  • Pathology disclosed typical features of parathyroid carcinoma with adjacent lymph node metastasis.
  • All three patients were relatively young and had extremely high intact parathyroid hormone (iPTH) level (15 to 31 times the upper limit of normal).
  • The first patient died of hypercalcemia and respiratory failure and the other 2 were treated successfully with surgical excision and, in case 2, combined chemotherapy and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12833192.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


32. Miwa S, Kadono Y, Sugata T, Mizokami A, Namiki M: Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes. Int J Clin Oncol; 2010 Feb;15(1):97-100
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes.
  • Here we present a case in which alternation of interferon-alpha (IFN-alpha) treatments was effective in treating pulmonary metastases and lymph node metastases from renal cell carcinoma (RCC).
  • A 56-year-old man underwent left radical nephrectomy under the diagnosis of left RCC.
  • The histological diagnosis was clear cell carcinoma G2, IFN-alpha, pT1b.
  • He subsequently underwent two operations for right pulmonary metastasis and right hilar lymph node metastasis.
  • However, multiple pulmonary metastases and left hilar lymph node metastasis occurred 11 months after discontinuation of Sumiferon.
  • Therefore, treatment with another natural IFN-alpha (OIF) was started.
  • Although OIF was continued for 7 months, pulmonary metastases and left hilar lymph node metastasis continued to progress.
  • Therefore, treatment was changed to Sumiferon, after which the pulmonary metastases and left hilar lymph node metastasis decreased in size.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Interferon-alpha / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis
  • [MeSH-minor] Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Interferon Cytokine Res. 1999 Dec;19(12 ):1343-9 [10638703.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2004 Jan;95(1):50-3 [14978941.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2006 Mar;97(3):598-601 [16613162.001]
  • [Cites] Int J Urol. 2008 Sep;15(9):848-50 [18786206.001]
  • [Cites] J Interferon Cytokine Res. 2001 Dec;21(12):1129-36 [11798471.001]
  • [Cites] Biomed Res. 2005 Jun;26(3):135-7 [16011307.001]
  • [Cites] Int J Oncol. 2006 Apr;28(4):965-70 [16525647.001]
  • [Cites] Ann Thorac Surg. 1994 Feb;57(2):339-44 [8311594.001]
  • (PMID = 20066455.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


33. Kakegawa S, Kawashima O, Sugano M, Nagashima T, Morishita Y: [Pleomorphic lung cancer; a clinicopathologic study]. Kyobu Geka; 2006 Feb;59(2):110-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary pleomorphic carcinoma is a comparatively rare histologic type of lung carcinoma, and the incidence among all lung carcinomas has been reported to be 0.4%.
  • We reported our experience with 8 patients who had been diagnosed as pulmonary pleomorphic carcinoma, and discussed clinicopathologically the preoperative diagnosis and treatment.
  • In 2 of 8 patients, preoperative transbronchial lung biopsy revealed spindle cell component, highly suggesting pulmonary pleomorphic carcinoma.
  • All patients underwent surgical treatment and 2 of then had incomplete resections because of intrathoracic disseminations or carcinomatous pericarditis.
  • Pathological findings showed invasions into the surrounding thoracic organs such as the chest wall, pericardium, adjacent pulmonary lobe or mediastinal pleura in 5 cases, intrapulmonary metastasis of the same lobe in 3 and lymph node involvement in 3.
  • Although the preoperative diagnosis of biphasic tumor such as pulmonary pleomorphic carcinoma is difficult, it is possible to suspect the diagnosis when sarcomatous components were detected by preoperative biopsy.
  • The efficacy of chemotherapy and radiotherapy have not been established yet, and thus we would like to emphasize that surgery might be the treatment of choice.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482903.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Halene S, Zieske A, Berliner N: Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol; 2006 Mar;3(3):165-8; quiz 169
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates.
  • INVESTIGATIONS: Physical examination, blood and urine cultures, MRI of the spine, echocardiogram, extensive serologies, serum and urine protein electrophoresis, immunofixation electrophoresis, bone-marrow aspiration and biopsy with flow cytometry, cytogenetics, and gene rearrangement studies, CT scan of the chest, abdomen and pelvis, whole-body PET, and lymph-node biopsy for histological examination, immunohistochemistry, and gene rearrangement studies.
  • DIAGNOSIS: Angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520806.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down






Advertisement